Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 6/20 | 0.61 |
| ▸ | CNR2 | P34972 | 8/20 | 0.52 |
| ▸ | CNR1 | P21554 | 5/20 | 0.52 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.52 |
| ▸ | MLNR | O43193 | 1/20 | 0.52 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.52 |
| ▸ | PDE9A | O76083 | 1/20 | 0.52 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.52 |
| ▸ | LDHA | P00338 | 1/20 | 0.52 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | HTR1A | P08908 | 1/20 | 0.52 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | DRD2 | P14416 | 1/20 | 0.52 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23791368 | 1.00 | OPRM1 (0.61) | OPRM1CNR2CNR1TRPV1MLNR | |
| SCHEMBL25560744 | 0.97 | OPRM1 (0.57) | OPRM1CNR2CNR1TRPV1MLNR | |
| SCHEMBL25560749 | 0.92 | OPRM1 (0.51) | OPRM1CNR2CNR1TRPV1MLNR | |
| SCHEMBL25560752 | 0.92 | OPRM1 (0.51) | OPRM1CNR2CNR1TRPV1MLNR | |
| SCHEMBL31545434 | 0.92 | OPRM1 (0.51) | OPRM1CNR2CNR1TRPV1MLNR | |
| SCHEMBL23065024 | 0.85 | OPRM1 (0.47) | OPRM1CNR2CNR1 | |
| SCHEMBL13214083 | 0.80 | OPRM1 (0.68) | OPRM1CNR2CNR1TRPV1MLNR | |
| SCHEMBL23868462 | 0.80 | OPRM1 (0.68) | OPRM1CNR2CNR1TRPV1MLNR | |
| SCHEMBL16084557 | 0.80 | OPRM1 (0.68) | OPRM1CNR2CNR1TRPV1MLNR | |
| SCHEMBL22821226 | 0.78 | OPRM1 (0.78) | OPRM1CNR2CNR1TRPV1MLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11654111-B2 | Oral solid cannabinoid formulations, methods for producing and using thereof | SATIPHARM AG (CH) | 2023-05-23 | — | — | US | disclosed |
| US-20220151952-A1 | Novel Nano-Formulation of Cannabidiol (CBD) and Other Cannabinoids for Treatment of Skin Diseases | MILANE MICHAEL (US) | 2022-05-19 | — | — | US | disclosed |
| US-20200121606-A1 | ORAL SOLID CANNABINOID FORMULATIONS, METHODS FOR PRODUCING AND USING THEREOF | GELPELL AG (CH) | 2020-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220151952-A1 | Novel Nano-Formulation of Cannabidiol (CBD) and Other Cannabinoids for Treatment of Skin Diseases | CNR2, CNR1, NCSTN | OPRM1 1395/4885CNR2 1/4885CNR1 2/4885 |
| US-11654111-B2 | Oral solid cannabinoid formulations, methods for producing and using thereof | CNR2, CNR1, GPR18 | OPRM1 18/4885CNR2 1/4885CNR1 2/4885 |
| US-20200121606-A1 | ORAL SOLID CANNABINOID FORMULATIONS, METHODS FOR PRODUCING AND USING THEREOF | CNR2, CNR1, GPR18 | OPRM1 18/4885CNR2 1/4885CNR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.